Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470922 | 0.85 | LPL (0.41) | LPLLIPGJAK2BTK | |
| SCHEMBL25226735 | 0.85 | LPL (0.41) | LPLLIPGJAK2BTK | |
| SCHEMBL5899734 | 0.84 | LPL (0.54) | LPLLIPGP4HBP2RX7ANPEP | |
| SCHEMBL746647 | 0.84 | JAK2 (0.42) | LPLLIPGJAK2BTKLMNA | |
| SCHEMBL30550009 | 0.84 | JAK2 (0.42) | LPLLIPGJAK2BTKLMNA | |
| SCHEMBL16815466 | 0.82 | JAK2 (0.53) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL22208077 | 0.81 | JAK2 (0.41) | LPLLIPGJAK2BTKTSHR | |
| SCHEMBL29634795 | 0.81 | JAK2 (0.41) | LPLLIPGJAK2BTKTSHR | |
| SCHEMBL23045909 | 0.81 | JAK2 (0.41) | LPLLIPGJAK2BTK | |
| SCHEMBL15649181 | 0.81 | JAK2 (0.41) | LPLLIPGJAK2BTKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250353828-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-11-20 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-119894869-A | Substituted biaryl kadetoxin-like quinolones having enhanced antiparasitic activity | 俄勒冈健康与科学大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536639-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | Oregon Health & Science University (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| WO-2025033037-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | 出光興産株式会社 | 2025-02-13 | — | — | WO | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2014009169-A1 | NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS | UNIVERSITE DE BORDEAUX 1 (FR) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009169-A1 | NEW PROCESS FOR PREPARING ARYLBORANES BY ARYLATION OF ORGANOBORON COMPOUNDS | UNIVERSITE DE BORDEAUX 1 (FR) | 2014-01-16 | — | — | WO | disclosed |
| EP-2684887-A1 | New process for preparing arylboranes by arylation of organoboron compounds | UNIVERSITE DE BORDEAUX I (FR) | 2014-01-15 | — | — | EP | disclosed |
| EP-2684887-A1 | New process for preparing arylboranes by arylation of organoboron compounds | UNIVERSITE DE BORDEAUX I (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8368062-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2013-02-05 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120007069-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| US-20110127513-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LPL 230/4885LIPG 232/4885JAK2 1797/4885 |
| US-20250353828-A1 | SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY | EPX, TFEB, EPHX1 | LPL 1736/4885LIPG 724/4885JAK2 1417/4885 |
| US-20120007069-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | VDAC2, VDAC1, VDAC3 | LPL 4810/4885LIPG 3725/4885JAK2 3325/4885 |
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | LPL 3028/4885LIPG 3200/4885JAK2 1620/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LPL 1442/4885LIPG 1293/4885JAK2 1688/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | LPL 230/4885LIPG 232/4885JAK2 1797/4885 |
| US-20110127513-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | VDAC2, VDAC1, VDAC3 | LPL 4810/4885LIPG 3725/4885JAK2 3325/4885 |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | CXCR1, ZC3HAV1L, ZC3HAV1 | LPL 1091/4885LIPG 1470/4885JAK2 1993/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | LPL 2944/4885LIPG 2120/4885JAK2 925/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LPL 1381/4885LIPG 1144/4885JAK2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.